Orgenesis Stock Performance
| ORGS Stock | USD 0.15 0.13 46.43% |
Orgenesis holds a performance score of 27 on a scale of zero to a hundred. The company holds a Beta of -12.65, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Orgenesis are expected to decrease by larger amounts. On the other hand, during market turmoil, Orgenesis is expected to outperform it. Use Orgenesis sortino ratio and the relationship between the downside variance and period momentum indicator , to analyze future returns on Orgenesis.
Risk-Adjusted Performance
Strong
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Orgenesis are ranked lower than 27 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak technical and fundamental indicators, Orgenesis unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Orgenesis |
Orgenesis Relative Risk vs. Return Landscape
If you would invest 11.00 in Orgenesis on September 30, 2025 and sell it today you would earn a total of 4.00 from holding Orgenesis or generate 36.36% return on investment over 90 days. Orgenesis is currently generating 57.9561% in daily expected returns and assumes 168.1238% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Orgenesis, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Orgenesis Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Orgenesis' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Orgenesis, and traders can use it to determine the average amount a Orgenesis' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.3447
| Best Portfolio | Best Equity | ORGS | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Orgenesis is performing at about 27% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Orgenesis by adding it to a well-diversified portfolio.
Orgenesis Fundamentals Growth
Orgenesis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Orgenesis, and Orgenesis fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Orgenesis Pink Sheet performance.
| Return On Equity | -7.27 | |||
| Return On Asset | -0.3 | |||
| Operating Margin | (16.54) % | |||
| Current Valuation | 23.01 M | |||
| Shares Outstanding | 4.77 M | |||
| Price To Earning | 7.52 X | |||
| Price To Book | 1.26 X | |||
| Price To Sales | 15.21 X | |||
| Revenue | 530 K | |||
| EBITDA | (54.07 M) | |||
| Cash And Equivalents | 2.3 M | |||
| Cash Per Share | 0.09 X | |||
| Total Debt | 22.62 M | |||
| Debt To Equity | 0.64 % | |||
| Book Value Per Share | (3.30) X | |||
| Cash Flow From Operations | (14.84 M) | |||
| Earnings Per Share | (8.00) X | |||
| Total Asset | 14.55 M | |||
| Retained Earnings | (176.62 M) | |||
| Current Asset | 5.29 M | |||
| Current Liabilities | 14.92 M | |||
About Orgenesis Performance
Assessing Orgenesis' fundamental ratios provides investors with valuable insights into Orgenesis' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Orgenesis is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 151 people.Things to note about Orgenesis performance evaluation
Checking the ongoing alerts about Orgenesis for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Orgenesis help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Orgenesis is way too risky over 90 days horizon | |
| Orgenesis has some characteristics of a very speculative penny stock | |
| Orgenesis appears to be risky and price may revert if volatility continues | |
| Orgenesis has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 530 K. Net Loss for the year was (64.92 M) with profit before overhead, payroll, taxes, and interest of 36.02 M. | |
| Orgenesis currently holds about 2.3 M in cash with (14.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09. | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Theres trouble ahead for stocks and gold, according to these indicators - MarketWatch |
- Analyzing Orgenesis' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Orgenesis' stock is overvalued or undervalued compared to its peers.
- Examining Orgenesis' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Orgenesis' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Orgenesis' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Orgenesis' pink sheet. These opinions can provide insight into Orgenesis' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Orgenesis Pink Sheet Analysis
When running Orgenesis' price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.